"C:\Program Files\Java\jdk1.8.0_181\bin\java.exe" "-javaagent:D:\Applications\IntelliJ\IntelliJ IDEA 2018.2.2\lib\idea_rt.jar=54998:D:\Applications\IntelliJ\IntelliJ IDEA 2018.2.2\bin" -Dfile.encoding=UTF-8 -classpath "C:\Program Files\Java\jdk1.8.0_181\jre\lib\charsets.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\deploy.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\access-bridge-64.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\cldrdata.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\dnsns.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\jaccess.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\jfxrt.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\localedata.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\nashorn.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\sunec.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\sunjce_provider.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\sunmscapi.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\sunpkcs11.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\ext\zipfs.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\javaws.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\jce.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\jfr.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\jfxswt.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\jsse.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\management-agent.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\plugin.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\resources.jar;C:\Program Files\Java\jdk1.8.0_181\jre\lib\rt.jar;C:\Users\umkcmax\Desktop\Lab2\ICP4\source code\NCBO_BioNLP\target\scala-2.11\classes;C:\Users\umkcmax\.ivy2\cache\aopalliance\aopalliance\jars\aopalliance-1.0.jar;C:\Users\umkcmax\.ivy2\cache\xmlenc\xmlenc\jars\xmlenc-0.52.jar;C:\Users\umkcmax\.ivy2\cache\xml-apis\xml-apis\jars\xml-apis-1.3.04.jar;C:\Users\umkcmax\.ivy2\cache\xerces\xercesImpl\jars\xercesImpl-2.9.1.jar;C:\Users\umkcmax\.ivy2\cache\xalan\xalan\jars\xalan-2.7.0.jar;C:\Users\umkcmax\.ivy2\cache\oro\oro\jars\oro-2.0.8.jar;C:\Users\umkcmax\.ivy2\cache\org.xerial.snappy\snappy-java\bundles\snappy-java-1.1.2.6.jar;C:\Users\umkcmax\.ivy2\cache\org.typelevel\macro-compat_2.11\jars\macro-compat_2.11-1.1.1.jar;C:\Users\umkcmax\.ivy2\cache\org.typelevel\machinist_2.11\jars\machinist_2.11-0.6.1.jar;C:\Users\umkcmax\.ivy2\cache\org.tukaani\xz\jars\xz-1.0.jar;C:\Users\umkcmax\.ivy2\cache\org.spire-math\spire_2.11\jars\spire_2.11-0.13.0.jar;C:\Users\umkcmax\.ivy2\cache\org.spire-math\spire-macros_2.11\jars\spire-macros_2.11-0.13.0.jar;C:\Users\umkcmax\.ivy2\cache\org.spark-project.spark\unused\jars\unused-1.0.0.jar;C:\Users\umkcmax\.ivy2\cache\org.sonatype.sisu.inject\cglib\jars\cglib-2.2.1-v20090111.jar;C:\Users\umkcmax\.ivy2\cache\org.slf4j\slf4j-log4j12\jars\slf4j-log4j12-1.7.16.jar;C:\Users\umkcmax\.ivy2\cache\org.slf4j\slf4j-api\jars\slf4j-api-1.7.25.jar;C:\Users\umkcmax\.ivy2\cache\org.slf4j\jul-to-slf4j\jars\jul-to-slf4j-1.7.16.jar;C:\Users\umkcmax\.ivy2\cache\org.slf4j\jcl-over-slf4j\jars\jcl-over-slf4j-1.7.16.jar;C:\Users\umkcmax\.ivy2\cache\org.scalanlp\breeze_2.11\jars\breeze_2.11-0.13.2.jar;C:\Users\umkcmax\.ivy2\cache\org.scalanlp\breeze-macros_2.11\jars\breeze-macros_2.11-0.13.2.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang.modules\scala-xml_2.11\bundles\scala-xml_2.11-1.0.4.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang.modules\scala-parser-combinators_2.11\bundles\scala-parser-combinators_2.11-1.0.4.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang\scalap\jars\scalap-2.11.8.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang\scala-reflect\jars\scala-reflect-2.11.8.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang\scala-library\jars\scala-library-2.11.8.jar;C:\Users\umkcmax\.ivy2\cache\org.scala-lang\scala-compiler\jars\scala-compiler-2.11.8.jar;C:\Users\umkcmax\.ivy2\cache\org.roaringbitmap\RoaringBitmap\bundles\RoaringBitmap-0.5.11.jar;C:\Users\umkcmax\.ivy2\cache\org.objenesis\objenesis\jars\objenesis-2.1.jar;C:\Users\umkcmax\.ivy2\cache\org.mortbay.jetty\jetty-util\jars\jetty-util-6.1.26.jar;C:\Users\umkcmax\.ivy2\cache\org.lz4\lz4-java\jars\lz4-java-1.4.0.jar;C:\Users\umkcmax\.ivy2\cache\org.json4s\json4s-jackson_2.11\jars\json4s-jackson_2.11-3.2.11.jar;C:\Users\umkcmax\.ivy2\cache\org.json4s\json4s-core_2.11\jars\json4s-core_2.11-3.2.11.jar;C:\Users\umkcmax\.ivy2\cache\org.json4s\json4s-ast_2.11\jars\json4s-ast_2.11-3.2.11.jar;C:\Users\umkcmax\.ivy2\cache\org.javassist\javassist\bundles\javassist-3.18.1-GA.jar;C:\Users\umkcmax\.ivy2\cache\org.htrace\htrace-core\jars\htrace-core-3.0.4.jar;C:\Users\umkcmax\.ivy2\cache\org.hamcrest\hamcrest-core\jars\hamcrest-core-1.1.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.media\jersey-media-jaxb\jars\jersey-media-jaxb-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.core\jersey-server\jars\jersey-server-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.core\jersey-common\jars\jersey-common-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.core\jersey-client\jars\jersey-client-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.containers\jersey-container-servlet-core\jars\jersey-container-servlet-core-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.containers\jersey-container-servlet\jars\jersey-container-servlet-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.jersey.bundles.repackaged\jersey-guava\bundles\jersey-guava-2.22.2.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2.external\javax.inject\jars\javax.inject-2.4.0-b34.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2.external\aopalliance-repackaged\jars\aopalliance-repackaged-2.4.0-b34.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2\osgi-resource-locator\jars\osgi-resource-locator-1.0.1.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2\hk2-utils\jars\hk2-utils-2.4.0-b34.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2\hk2-locator\jars\hk2-locator-2.4.0-b34.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish.hk2\hk2-api\jars\hk2-api-2.4.0-b34.jar;C:\Users\umkcmax\.ivy2\cache\org.glassfish\javax.json\bundles\javax.json-1.0.4.jar;C:\Users\umkcmax\.ivy2\cache\org.fusesource.leveldbjni\leveldbjni-all\bundles\leveldbjni-all-1.8.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.jettison\jettison\bundles\jettison-1.1.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.janino\janino\jars\janino-3.0.8.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.janino\commons-compiler\jars\commons-compiler-3.0.8.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.jackson\jackson-xc\jars\jackson-xc-1.9.13.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.jackson\jackson-mapper-asl\jars\jackson-mapper-asl-1.9.13.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.jackson\jackson-jaxrs\jars\jackson-jaxrs-1.9.13.jar;C:\Users\umkcmax\.ivy2\cache\org.codehaus.jackson\jackson-core-asl\jars\jackson-core-asl-1.9.13.jar;C:\Users\umkcmax\.ivy2\cache\org.bouncycastle\bcprov-jdk15on\jars\bcprov-jdk15on-1.52.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.zookeeper\zookeeper\jars\zookeeper-3.4.6.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.xbean\xbean-asm5-shaded\bundles\xbean-asm5-shaded-4.4.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-unsafe_2.11\jars\spark-unsafe_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-tags_2.11\jars\spark-tags_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-streaming_2.11\jars\spark-streaming_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-sql_2.11\jars\spark-sql_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-sketch_2.11\jars\spark-sketch_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-network-shuffle_2.11\jars\spark-network-shuffle_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-network-common_2.11\jars\spark-network-common_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-mllib_2.11\jars\spark-mllib_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-mllib-local_2.11\jars\spark-mllib-local_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-launcher_2.11\jars\spark-launcher_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-kvstore_2.11\jars\spark-kvstore_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-graphx_2.11\jars\spark-graphx_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-core_2.11\jars\spark-core_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.spark\spark-catalyst_2.11\jars\spark-catalyst_2.11-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-jackson\jars\parquet-jackson-1.8.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-hadoop\jars\parquet-hadoop-1.8.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-format\jars\parquet-format-2.3.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-encoding\jars\parquet-encoding-1.8.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-common\jars\parquet-common-1.8.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.parquet\parquet-column\jars\parquet-column-1.8.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.orc\orc-mapreduce\jars\orc-mapreduce-1.4.4-nohive.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.orc\orc-core\jars\orc-core-1.4.4-nohive.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.lucene\lucene-sandbox\jars\lucene-sandbox-4.10.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.lucene\lucene-queryparser\jars\lucene-queryparser-4.10.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.lucene\lucene-queries\jars\lucene-queries-4.10.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.lucene\lucene-core\jars\lucene-core-4.10.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.lucene\lucene-analyzers-common\jars\lucene-analyzers-common-4.10.3.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.ivy\ivy\jars\ivy-2.4.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.httpcomponents\httpcore\jars\httpcore-4.4.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.httpcomponents\httpclient\jars\httpclient-4.5.2.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-yarn-server-common\jars\hadoop-yarn-server-common-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-yarn-common\jars\hadoop-yarn-common-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-yarn-client\jars\hadoop-yarn-client-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-yarn-api\jars\hadoop-yarn-api-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-mapreduce-client-shuffle\jars\hadoop-mapreduce-client-shuffle-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-mapreduce-client-jobclient\jars\hadoop-mapreduce-client-jobclient-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-mapreduce-client-core\jars\hadoop-mapreduce-client-core-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-mapreduce-client-common\jars\hadoop-mapreduce-client-common-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-mapreduce-client-app\jars\hadoop-mapreduce-client-app-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-hdfs\jars\hadoop-hdfs-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-common\jars\hadoop-common-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-client\jars\hadoop-client-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-auth\jars\hadoop-auth-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.hadoop\hadoop-annotations\jars\hadoop-annotations-2.6.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.directory.server\apacheds-kerberos-codec\bundles\apacheds-kerberos-codec-2.0.0-M15.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.directory.server\apacheds-i18n\bundles\apacheds-i18n-2.0.0-M15.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.directory.api\api-util\bundles\api-util-1.0.0-M20.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.directory.api\api-asn1-api\bundles\api-asn1-api-1.0.0-M20.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.curator\curator-recipes\bundles\curator-recipes-2.6.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.curator\curator-framework\bundles\curator-framework-2.6.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.curator\curator-client\bundles\curator-client-2.6.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.commons\commons-math3\jars\commons-math3-3.4.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.commons\commons-lang3\jars\commons-lang3-3.5.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.commons\commons-crypto\jars\commons-crypto-1.0.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.commons\commons-compress\jars\commons-compress-1.4.1.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.avro\avro-mapred\jars\avro-mapred-1.7.7-hadoop2.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.avro\avro-ipc\jars\avro-ipc-1.7.7-tests.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.avro\avro-ipc\jars\avro-ipc-1.7.7.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.avro\avro\jars\avro-1.7.7.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.arrow\arrow-vector\jars\arrow-vector-0.8.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.arrow\arrow-memory\jars\arrow-memory-0.8.0.jar;C:\Users\umkcmax\.ivy2\cache\org.apache.arrow\arrow-format\jars\arrow-format-0.8.0.jar;C:\Users\umkcmax\.ivy2\cache\org.antlr\antlr4-runtime\jars\antlr4-runtime-4.7.jar;C:\Users\umkcmax\.ivy2\cache\net.sourceforge.f2j\arpack_combined_all\jars\arpack_combined_all-0.1.jar;C:\Users\umkcmax\.ivy2\cache\net.sf.py4j\py4j\jars\py4j-0.10.7.jar;C:\Users\umkcmax\.ivy2\cache\net.sf.opencsv\opencsv\jars\opencsv-2.3.jar;C:\Users\umkcmax\.ivy2\cache\net.razorvine\pyrolite\jars\pyrolite-4.13.jar;C:\Users\umkcmax\.ivy2\cache\net.java.dev.jets3t\jets3t\jars\jets3t-0.9.4.jar;C:\Users\umkcmax\.ivy2\cache\net.iharder\base64\jars\base64-2.3.8.jar;C:\Users\umkcmax\.ivy2\cache\log4j\log4j\bundles\log4j-1.2.17.jar;C:\Users\umkcmax\.ivy2\cache\junit\junit\jars\junit-4.10.jar;C:\Users\umkcmax\.ivy2\cache\joda-time\joda-time\jars\joda-time-2.9.9.jar;C:\Users\umkcmax\.ivy2\cache\jline\jline\jars\jline-0.9.94.jar;C:\Users\umkcmax\.ivy2\cache\javax.xml.bind\jaxb-api\jars\jaxb-api-2.2.7.jar;C:\Users\umkcmax\.ivy2\cache\javax.ws.rs\javax.ws.rs-api\jars\javax.ws.rs-api-2.0.1.jar;C:\Users\umkcmax\.ivy2\cache\javax.validation\validation-api\jars\validation-api-1.1.0.Final.jar;C:\Users\umkcmax\.ivy2\cache\javax.servlet\javax.servlet-api\jars\javax.servlet-api-3.1.0.jar;C:\Users\umkcmax\.ivy2\cache\javax.inject\javax.inject\jars\javax.inject-1.jar;C:\Users\umkcmax\.ivy2\cache\javax.annotation\javax.annotation-api\jars\javax.annotation-api-1.2.jar;C:\Users\umkcmax\.ivy2\cache\javax.activation\activation\jars\activation-1.1.1.jar;C:\Users\umkcmax\.ivy2\cache\io.netty\netty-all\jars\netty-all-4.1.17.Final.jar;C:\Users\umkcmax\.ivy2\cache\io.netty\netty\bundles\netty-3.9.9.Final.jar;C:\Users\umkcmax\.ivy2\cache\io.dropwizard.metrics\metrics-jvm\bundles\metrics-jvm-3.1.5.jar;C:\Users\umkcmax\.ivy2\cache\io.dropwizard.metrics\metrics-json\bundles\metrics-json-3.1.5.jar;C:\Users\umkcmax\.ivy2\cache\io.dropwizard.metrics\metrics-graphite\bundles\metrics-graphite-3.1.5.jar;C:\Users\umkcmax\.ivy2\cache\io.dropwizard.metrics\metrics-core\bundles\metrics-core-3.1.5.jar;C:\Users\umkcmax\.ivy2\cache\io.airlift\aircompressor\jars\aircompressor-0.8.jar;C:\Users\umkcmax\.ivy2\cache\edu.stanford.nlp\stanford-parser\jars\stanford-parser-3.9.1.jar;C:\Users\umkcmax\.ivy2\cache\edu.stanford.nlp\stanford-corenlp\jars\stanford-corenlp-3.9.1-models.jar;C:\Users\umkcmax\.ivy2\cache\edu.stanford.nlp\stanford-corenlp\jars\stanford-corenlp-3.9.1.jar;C:\Users\umkcmax\.ivy2\cache\de.jollyday\jollyday\jars\jollyday-0.4.9.jar;C:\Users\umkcmax\.ivy2\cache\commons-net\commons-net\jars\commons-net-2.2.jar;C:\Users\umkcmax\.ivy2\cache\commons-logging\commons-logging\jars\commons-logging-1.2.jar;C:\Users\umkcmax\.ivy2\cache\commons-lang\commons-lang\jars\commons-lang-2.6.jar;C:\Users\umkcmax\.ivy2\cache\commons-io\commons-io\jars\commons-io-2.4.jar;C:\Users\umkcmax\.ivy2\cache\commons-httpclient\commons-httpclient\jars\commons-httpclient-3.1.jar;C:\Users\umkcmax\.ivy2\cache\commons-digester\commons-digester\jars\commons-digester-1.8.jar;C:\Users\umkcmax\.ivy2\cache\commons-configuration\commons-configuration\jars\commons-configuration-1.6.jar;C:\Users\umkcmax\.ivy2\cache\commons-collections\commons-collections\jars\commons-collections-3.2.2.jar;C:\Users\umkcmax\.ivy2\cache\commons-codec\commons-codec\jars\commons-codec-1.11.jar;C:\Users\umkcmax\.ivy2\cache\commons-cli\commons-cli\jars\commons-cli-1.2.jar;C:\Users\umkcmax\.ivy2\cache\commons-beanutils\commons-beanutils-core\jars\commons-beanutils-core-1.8.0.jar;C:\Users\umkcmax\.ivy2\cache\commons-beanutils\commons-beanutils\jars\commons-beanutils-1.7.0.jar;C:\Users\umkcmax\.ivy2\cache\com.vlkan\flatbuffers\jars\flatbuffers-1.2.0-3f79e055.jar;C:\Users\umkcmax\.ivy2\cache\com.univocity\univocity-parsers\jars\univocity-parsers-2.5.9.jar;C:\Users\umkcmax\.ivy2\cache\com.twitter\chill_2.11\jars\chill_2.11-0.8.4.jar;C:\Users\umkcmax\.ivy2\cache\com.twitter\chill-java\jars\chill-java-0.8.4.jar;C:\Users\umkcmax\.ivy2\cache\com.thoughtworks.paranamer\paranamer\bundles\paranamer-2.8.jar;C:\Users\umkcmax\.ivy2\cache\com.ning\compress-lzf\bundles\compress-lzf-1.0.3.jar;C:\Users\umkcmax\.ivy2\cache\com.jamesmurty.utils\java-xmlbuilder\jars\java-xmlbuilder-1.1.jar;C:\Users\umkcmax\.ivy2\cache\com.io7m.xom\xom\jars\xom-1.2.10.jar;C:\Users\umkcmax\.ivy2\cache\com.googlecode.json-simple\json-simple\bundles\json-simple-1.1.1.jar;C:\Users\umkcmax\.ivy2\cache\com.googlecode.efficient-java-matrix-library\ejml\jars\ejml-0.23.jar;C:\Users\umkcmax\.ivy2\cache\com.google.protobuf\protobuf-java\bundles\protobuf-java-3.2.0.jar;C:\Users\umkcmax\.ivy2\cache\com.google.inject\guice\jars\guice-3.0.jar;C:\Users\umkcmax\.ivy2\cache\com.google.guava\guava\jars\guava-11.0.2.jar;C:\Users\umkcmax\.ivy2\cache\com.google.code.gson\gson\jars\gson-2.2.4.jar;C:\Users\umkcmax\.ivy2\cache\com.google.code.findbugs\jsr305\jars\jsr305-3.0.2.jar;C:\Users\umkcmax\.ivy2\cache\com.github.scopt\scopt_2.10\jars\scopt_2.10-3.4.0.jar;C:\Users\umkcmax\.ivy2\cache\com.github.rwl\jtransforms\jars\jtransforms-2.4.0.jar;C:\Users\umkcmax\.ivy2\cache\com.github.luben\zstd-jni\bundles\zstd-jni-1.3.2-2.jar;C:\Users\umkcmax\.ivy2\cache\com.github.fommil.netlib\core\jars\core-1.1.2.jar;C:\Users\umkcmax\.ivy2\cache\com.fasterxml.jackson.module\jackson-module-scala_2.11\bundles\jackson-module-scala_2.11-2.6.7.1.jar;C:\Users\umkcmax\.ivy2\cache\com.fasterxml.jackson.module\jackson-module-paranamer\bundles\jackson-module-paranamer-2.7.9.jar;C:\Users\umkcmax\.ivy2\cache\com.fasterxml.jackson.core\jackson-databind\bundles\jackson-databind-2.6.7.1.jar;C:\Users\umkcmax\.ivy2\cache\com.fasterxml.jackson.core\jackson-core\bundles\jackson-core-2.7.9.jar;C:\Users\umkcmax\.ivy2\cache\com.fasterxml.jackson.core\jackson-annotations\bundles\jackson-annotations-2.6.7.jar;C:\Users\umkcmax\.ivy2\cache\com.esotericsoftware\minlog\bundles\minlog-1.3.0.jar;C:\Users\umkcmax\.ivy2\cache\com.esotericsoftware\kryo-shaded\bundles\kryo-shaded-3.0.3.jar;C:\Users\umkcmax\.ivy2\cache\com.clearspring.analytics\stream\jars\stream-2.7.0.jar;C:\Users\umkcmax\.ivy2\cache\com.chuusai\shapeless_2.11\bundles\shapeless_2.11-2.3.2.jar;C:\Users\umkcmax\.ivy2\cache\com.carrotsearch\hppc\bundles\hppc-0.7.2.jar;C:\Users\umkcmax\.ivy2\cache\com.apple\AppleJavaExtensions\jars\AppleJavaExtensions-1.4.jar" RESTClientGet Bioconcept examples_data/ex.pmid PubTator
30184615|t|Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.
30184615|a|Background/Aims: The outcome of local treatment for advanced non-small cell lung cancer (NSCLC) remains poor, with therapies such as induction chemotherapy (IC) yielding conflicting results. This study aimed to assess the clinicopathologic and prognostic significance of the excision repair cross-complementation group 1 (ERCC1), beclin-1, and glucose-regulated protein of molecular mass 78 (GRP78) in patients with locally advanced NSCLC receiving docetaxel-platinum IC, along with efficacy and safety. Methods: This is a retrospective observational cohort study. We reviewed medical records of 31 NSCLC patients receiving docetaxel-platinum IC, and conducted immunohistochemical staining of ERCC1, beclin-1, and GRP78. Results: Response rate was 67.8% with 10.7 months of median relapse-free survival (RFS) and 23.1 months of median overall survival (OS), and no treatment-related death was reported. High expression of ERCC1, beclin-1, and GRP78 was identified in 67.7%, 87.1%, and 67.7%, respectively. Expression of ERCC1 and GRP78 did not reveal statistical significance in survival, whereas high beclin-1 expression revealed longer OS (7.6 months vs. 23.2 months; log-rank p = 0.024). In multivariate analysis, histologic differentiation (hazard ratio [HR], 3.48; p < 0.001), stage (HR, 8.5; p = 0.024), and adjuvant treatment (HR, 16.1; p = 0.001) were related to RFS, and in OS, stage (HR, 5.4; p = 0.037), adjuvant treatment (HR, 8.6; p = 0.004), and beclin-1 expression (HR, 8.2; p = 0.011) were identified as significant prognostic factors. Conclusions: Our findings suggest that high beclin-1 expression predicts longer survival in locally advanced NSCLC and docetaxel-platinum IC is a treatment option that deserves consideration.
30184615	19	27	beclin-1	Gene	8678
30184615	48	74	non-small cell lung cancer	Disease	D002289
30184615	78	86	patients	Species	9606
30184615	97	106	docetaxel	Chemical	C067311
30184615	107	115	platinum	Chemical	D010984
30184615	201	227	non-small cell lung cancer	Disease	D002289
30184615	229	234	NSCLC	Disease	D002289
30184615	415	460	excision repair cross-complementation group 1	Gene	2067
30184615	462	467	ERCC1	Gene	2067
30184615	470	478	beclin-1	Gene	8678
30184615	484	491	glucose	Chemical	D005947
30184615	532	537	GRP78	Gene	3309
30184615	542	550	patients	Species	9606
30184615	573	578	NSCLC	Disease	D002289
30184615	589	598	docetaxel	Chemical	C067311
30184615	599	607	platinum	Chemical	D010984
30184615	739	744	NSCLC	Disease	D002289
30184615	745	753	patients	Species	9606
30184615	764	773	docetaxel	Chemical	C067311
30184615	774	782	platinum	Chemical	D010984
30184615	833	838	ERCC1	Gene	2067
30184615	840	848	beclin-1	Gene	8678
30184615	854	859	GRP78	Gene	3309
30184615	921	942	relapse-free survival	Disease	D012008
30184615	944	947	RFS	Disease	D012008
30184615	975	991	overall survival	Disease	D011475
30184615	993	995	OS	Disease	D011475
30184615	1023	1028	death	Disease	D003643
30184615	1062	1067	ERCC1	Gene	2067
30184615	1069	1077	beclin-1	Gene	8678
30184615	1083	1088	GRP78	Gene	3309
30184615	1160	1165	ERCC1	Gene	2067
30184615	1170	1175	GRP78	Gene	3309
30184615	1242	1250	beclin-1	Gene	8678
30184615	1278	1280	OS	Disease	D011475
30184615	1511	1514	RFS	Disease	D012008
30184615	1523	1525	OS	Disease	D011475
30184615	1600	1608	beclin-1	Gene	8678
30184615	1736	1744	beclin-1	Gene	8678
30184615	1801	1806	NSCLC	Disease	D002289
30184615	1811	1820	docetaxel	Chemical	C067311
30184615	1821	1829	platinum	Chemical	D010984

30184548|t|Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts.
30184548|a|BACKGROUND/AIMS: The malignant biological behavior of gastric cancer(GC) is not only determined by cancer cells alone, but also closely regulated by the microenvironment. Fibroblasts represent a large proportion of the components in the tumor microenvironment, and they promote the development of disease. Currently, accumulating evidence suggests that exosomes can function as intercellular transport systems to relay their contents, especially microRNAs(miRNAs). METHODS: First, we detected the highly-expressed level of miR-27a in exosomes isolated from gastric cancer cells by qRT-PCR. MiR-27a -over-expressed models in vitro and in vivo were established to investigate the transformation of cancer-associated fibroblasts observed by Western blotting, and the malignant behavior of gastric cancer cells using the methods CCK8 and Transwell. Moreover, the downregulation of CSRP2 in fibroblasts was used to evaluate the promotion of malignancy of gastric cancer using the methods CCK8 and Transwell. RESULTS: In this study, we found a marked high level of miR-27a in exosomes derived from GC cells. miR-27a was found to function an oncogene that not only induced the reprogramming of fibroblasts into cancer-associated fibroblasts(CAFs), but also promoted the proliferation, motility and metastasis of cancer cells in vitro and in vivo. Conversely, CAFs with over-expression of miR-27a could pleiotropically increase the malignant behavior of the GC cells. For the first time, we revealed that CSRP2 is a downstream target of miR-27a. CSRP2 downregulation could increase the proliferation and motility of GC cells. CONCLUSION: Thus, this report indicates that miR-27a in exosomes derived from GC cells has a crucial impact on the microenvironment and may be used as a potential therapeutic target in the treatment of GC.

30183753|t|Dosimetric superiority of IMRT with jaw tracking technique for whole esophagus and T-shaped field radiotherapy in advanced esophageal cancer.
30183753|a|PURPOSE: For whole esophagus and T-shaped field radiotherapy using intensity modulated radiotherapy (IMRT) technique in advanced esophageal cancer, lower absorbed doses to lung and heart remains a challenge. The aim of this study was to investigate the dosimetric superiority in IMRT plans with jaw tracking technique for whole esophagus radiotherapy. METHODS AND MATERIALS: Thirty-two patients with esophageal cancer were subjected to IMRT treatment plans using Eclipse treatment planning system. For every patient, four different plans were generated with six gantry angles: six large fields IMRT plans with fixed jaw (6F-IMRT), six large fields IMRT plans with jaw tracking technique (6F-IMRT-T), twelve small fields IMRT plans with fixed jaw (12F-IMRT), and twelve small fields IMRT plans with jaw tracking technique (12F-IMRT-T). Dosimetric evaluation was assessed for all plans. RESULTS: For every technique, there were no differences in planning target volume (PTV) coverage and conformity. 6F-IMRT-T plans could significantly reduce lung irradiation with 7.9% (P<0.001) reduction in V5lung and 2.5% (P<0.001) reduction in V20 lung respectively compared to 6F-IMRT plans. 12F-IMRT-T plans resulted in superior plans compared to 12-IMRT plans with a reduction of 2.9% (P<0.001) in V5lung and 0.9% (P<0.001) in V20 lung, respectively. For heart irradiation, 6F-IMRT-T and 12F-IMRT-T plans were slightly superior to 6F-IMRT and 12-IMRT plans respectively with a reduction of 1.1 Gy and 0.5 Gy in the respective mean doses. CONCLUSIONS: By the use of jaw tracking technique, the IMRT plans resulted in further lung and heart sparing compared to fixed jaw plans for radiotherapy in esophageal cancer.
30183753	123	140	esophageal cancer	Disease	D004938
30183753	271	288	esophageal cancer	Disease	D004938
30183753	528	536	patients	Species	9606
30183753	542	559	esophageal cancer	Disease	D004938
30183753	650	657	patient	Species	9606
30183753	889	897	12F-IMRT	Chemical
30183753	1110	1113	PTV	Species	187978
30183753	1826	1843	esophageal cancer	Disease	D004938

30183684|t|Method for optimizing planning target volume margin for patients receiving lung stereotactic body radiotherapy.
30183684|a|Lung stereotactic-body radiotherapy (SBRT) places additional requirements on targeting accuracy over standard approaches. In treatment planning, a tumour volume is geometrically expanded and the resulting planning target volume (PTV) is covered with full dose. This ensures full dose delivery despite various uncertainties encountered during treatment. _#13; _#13; We developed a retrospective technique for optimizing the PTV expansion for a patient population. The method relies on deformable image registration (DIR) of the planning CT to a treatment cone-beam CT (CBCT). The resulting transformation is used to map the planned target onto the treatment geometry, allowing the computation of the achieved target/PTV overlap. _#13; _#13; Basic validation of the method was performed using an anthropomorphic respiratory motion phantom. A self-validation technique was also implemented to allow estimation of the DIR error for the data being analyzed. Our workflow was used to retrospectively optimize PTV margin for 25 patients treated over 93 fractions. Targets for these patients were contoured on four-dimensional CT images. SBRT delivery followed CBCT acquisition and a couch correction. A post-treatment CBCT was also acquired in some cases. _#13; _#13; Our basic validation demonstrated that the DIR-based technique is capable of transforming targets volumes from planning CTs to treatment CBCTs with sub-mm accuracy. Our clinical analysis showed that the minimum percentages of target volumes covered for 3, 4, and 5mm PTV margins were 92.1, 97.6, and 99.2, respectively. Analyzing data acquired before and just after treatment demonstrated that margins exceeding 5mm did not significantly improve coverage. Finally, a 5mm PTV margin achieved >= 95% target volume coverage with >= 95% probability._#13; _#13; Our technique is accurate, automated, self-validating, and incorporates complex ITV shapes/deformations to allow PTV margin optimization. The analysis of clinical data indicates a 5mm PTV margin is optimal for our process. This approach is generalizable to other disease sites and treatment strategies. _#13.

30183677|t|An augmented correlation framework for the estimation of tumour translational and rotational motion during external beam radiotherapy treatments using intermittent monoscopic X-ray imaging and an external respiratory signal.
30183677|a|Increasing evidence shows that intrafraction tumour motion monitoring must include both six degrees of freedom (6DoF): 3D translations and 3D rotations. Existing real- time algorithms for 6DoF target motion estimation requires continuous intrafraction fluoroscopic imaging at high frequency, thereby exposing patients to additional high imaging dose. This paper presents the first method capable of 6DoF motion monitoring using intermittent 2D kV imaging and a continuous external respiratory signal._#13; Method: Our approach is to optimise a state-augmented linear correlation model between an external signal and internal 6DoF motion. In standard treatments, the model can be built using information obtained during pre-treatment CBCT. Real-time 6DoF tumor motion can then be estimated using just the external signal. Intermittent intrafraction kV images are used to update the model parameters, accounting for changes in correlation and baseline shifts._#13; The method was evaluated in silico using data from 6 lung SABR patients, with the internal tumour motion recorded with electromagnetic beacons and the external signal from a bellows belt. Projection images from CBCT (10 Hz) and intermittent kV images were simulated by projecting the 3D Calypso beacon positions onto an imager. IMRT and VMAT treatments were simulated with increasing imaging update intervals: 0.1 s, 1 s, 3 s, 10 s and 30 s._#13; Results: For all the tested clinical scenarios, translational motion estimates with our method had sub-mm accuracy (mean) and precision (standard deviation) while rotational motion estimates were accurate to <1   and precise to 2  . Motion estimation errors increased as the imaging update interval increased. With the largest imaging update interval (30 s), the errors were 0.1  0.6 mm, -0.0  0.7 mm and 0.1  0:9 mm for translation in the Left-Right, Superior-Inferior and Anterior-Posterior directions, respectively, and 0.1  1.3  , -0.3  2.0   and 0.1  0:9   for rotation around the aforementioned axes for both VMAT and IMRT treatments.

30183476|t|Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer.
30183476|a|Small cell lung cancer (SCLC) is a malignant neuroendocrine tumor with very high mortality. Effective new therapy for advanced SCLC patients is urgently needed. By screening a FDA-approved drug library, we identified a cardiac glycoside (CG), namely digoxin (an inhibitor of cellular Na+/K+ ATPase pump), which was highly effective in inhibiting SCLC cell growth. Intriguing findings showed that NaCl supplement markedly enhanced the anti-tumor activities of digoxin in both in vitro and in vivo models of SCLC. Subsequent analysis revealed that this novel combination of digoxin/NaCl caused an up-regulation of intracellular Na+ and Ca2+ levels with an induction of higher resting membrane potential of SCLC cells. We also found that this combination lead to morphological shrinking of SCLC cells, together with high levels of cytochrome C release. Lastly, our data revealed that NaCl supplement was able to induce the expression of ATP1A1 (a Na+/K+ ATPase subunit), in which contributes directly to the increased sensitivity of SCLC cells to digoxin. Thus, this is the first demonstration that NaCl is a potent supplement necessitating superior anti-cancer effects of digoxin for SCLC. Further, our study suggests that digoxin treatment could need to be combined with NaCl supplement in future clinical trial of SCLC, particularly where low Na+ is often present in SCLC patients.

30183374|t|Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain.
30183374|a|Small cell lung cancer (SCLC) is the most aggressive histologic subtype of lung cancer, with a strong predilection for early brain metastases. Despite efforts and advances in new therapeutics for SCLC, the prognosis of patients with SCLC with brain metastases is consistently poor. Therefore, a better understanding of the mechanisms of SCLC brain metastasis is important in improving current treatments. In this study, elevated S100A16 levels were associated with SCLC brain metastases, which was a possible secondary event arising from the brain metastatic microenvironment. Using an in vitro cell coculture system, we found that the coculturing of SCLC cells with human brain microvascular endothelial cells (HBMECs) led to an increased expression of S100A16 in SCLC cells. Conversely, treatment of HBMECs with GW4869, an inhibitor of exosome release, significantly blocked this effect in the cocultured SCLC cells. Alternatively, the results from Western blot analyses and immunofluorescence indicated that the HBMEC exosomes purified by ultracentrifugation also induced the elevation and translocation from the cytoplasm to the nucleus of S100A16 in the recipient SCLC cells. The inhibition experiments demonstrated that elevated S100A16 contributed a benefit of HBMEC exosomes for the survival of the recipient SCLC cells under stress. Moreover, the elevation of S100A16 in SCLC cells prevented the loss of mitochondrial membrane potential (    m) and enhanced resistance to apoptosis under stressful conditions, which were determined by Annexin V/propidium iodide and JC-1 assay. Further results showed that the S100A16-mediated protective effect was caused by the presence of an important element in     m, prohibitin (PHB)-1, a protein in the mitochondrial inner membrane. Conversely, the delivery of PHB-1 siRNAs into S100A16 overexpressing SCLC cells weakened these protective effects. Our findings suggest that elevated S100A16 plays an active role in facilitating the survival of SCLC cells through modulating the mitochondrial function, identifying S100A16 as an important potential target in SCLC brain metastasis.-Xu, Z.-H., Miao, Z.-W., Jiang, Q.-Z., Gan, D.-X., Wei, X.-G., Xue, X.-Z., Li, J.-Q., Zheng, F., Qin, X.-X., Fang, W.-G., Chen, Y.-H., Li. B. Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small cell lung cancer cell survival in brain.

30183201|t|Limbic encephalitis associated with antibodies against the a-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor: a case report.
30183201|a|We report a case of a 51-year-old man with limbic encephalitis (LE) associated with antibodies against the a-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor (AMPAR). The patient presented with anterograde memory loss for 2 months. Cranial magnetic resonance and electroencephalogram were normal. AMPAR antibodies were found in blood serum and cerebrospinal fluid. All other test results were unremarkable. CT scans found a tumor in the right lobus superior pulmonis. A CT-guided needle biopsy was performed and pathological results showed small cell lung cancer (SCLC). The patient was diagnosed with LE associated with AMPAR antibodies and SCLC. Three months after immunotherapy and tumor removal, patient's memory was partially restored. We recommend that AMPAR antibodies should be detected in patients with classic LE with or without tumor. Prompt treatment of the tumor and immunotherapy are important.
30183201	0	19	Limbic encephalitis	Disease	D020363
30183201	59	111	a-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid	Chemical
30183201	171	174	man	Species	9606
30183201	180	199	limbic encephalitis	Disease	D020363
30183201	201	203	LE	Disease	D020363
30183201	244	296	a-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid	Chemical
30183201	319	326	patient	Species	9606
30183201	354	365	memory loss	Disease	D008569
30183201	572	577	tumor	Disease	D009369
30183201	688	710	small cell lung cancer	Disease	D055752
30183201	712	716	SCLC	Disease	D055752
30183201	723	730	patient	Species	9606
30183201	750	752	LE	Disease	D020363
30183201	790	794	SCLC	Disease	D055752
30183201	833	838	tumor	Disease	D009369
30183201	848	855	patient	Species	9606
30183201	946	954	patients	Species	9606
30183201	968	970	LE	Disease	D020363
30183201	987	992	tumor	Disease	D009369
30183201	1018	1023	tumor	Disease	D009369

30183078|t|Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.
30183078|a|Cancer precision medicine largely relies on knowledge about genetic aberrations in tumors and next-generation-sequencing studies have shown a high mutational complexity in many cancers. Although a large number of the observed mutations is believed to be not causally linked with cancer, the functional effects of many rare mutations but also of combinations of driver mutations are often unknown. Here, we perform a systems analysis of a model of EGFR-mutated non-small cell lung cancer resistant to targeted therapy that integrates whole exome sequencing, global time-course discovery phosphoproteomics and computational modeling to identify functionally relevant molecular alterations. Our approach allows for a complexity reduction from over 2,000 genetic events potentially involved in mediating resistance to only 44 phosphoproteins and 35 topologically close genetic alterations. We perform single- and combination-drug testing against the predicted phosphoproteins and discovered that targeting of HSPB1, DBNL and AKT1 showed potent anti-proliferative effects overcoming resistance against EGFR-inhibitory therapy. Our approach may therefore be used to complement mutational profiling to identify functionally relevant molecular aberrations and propose combination therapies across cancers. This article is protected by copyright. All rights reserved.

30183073|t|Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.
30183073|a|mTOR pathway inhibitors such as rapalogs represent a promising tool to induce functional memory CD8 T cells. In this study, we investigated the combination of temsirolimus with anticancer vaccines. Using various designs of cancer vaccines (short and long peptides or the B subunit of Shiga toxin as an antigen delivery vector) and tumor models (melanoma, lung and colon cancer), we showed that the administration of temsirolimus efficiently decreased tumor growth and enhanced tumor-specific CD8 T-cell responses induced by vaccination. Furthermore, tumor-specific CD8 T cells induced by the bi-therapy (vaccine + temsirolimus) exhibit phenotypic characteristics of central memory (CD127+ CD62L+ ) CD8 T cells compared to vaccination alone. We demonstrated that regulatory CD4 T cells (Tregs ) expansion in vivo limits the efficacy of the bi-therapy by altering the antitumor CD8 T-cell responses. Finally, the use of a small molecule CCR4 antagonist to prevent Tregs induction considerably improved the efficacy of the bi-therapy by enhancing CD8 T cells-mediated antitumor immunity. Taken together, this study highlights the potential interest of combining cancer vaccines with drugs that promote memory CD8 T cells and inhibit Tregs . This article is protected by copyright. All rights reserved.

java.io.IOException: Server returned HTTP response code: 400 for URL: https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/RESTful/tmTool.cgi/Bioconcept//PubTator/
	at sun.net.www.protocol.http.HttpURLConnection.getInputStream0(HttpURLConnection.java:1894)
	at sun.net.www.protocol.http.HttpURLConnection.getInputStream(HttpURLConnection.java:1492)
	at sun.net.www.protocol.https.HttpsURLConnectionImpl.getInputStream(HttpsURLConnectionImpl.java:263)
	at RESTClientGet.main(RESTClientGet.java:43)

Process finished with exit code 0
